EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Amivantamab-vmjw
Should clinicians be aware of any drug interactions? [...]there are no drug interactions to watch for with this product. Overall, the approval of amivantamab is a positive development for patients with lung cancer, and it adds another targeted option for those patients with limited therapy options a...
Gespeichert in:
| Veröffentlicht in: | Oncology (Williston Park, N.Y.) N.Y.), 2022-03, Vol.36 (3), p.186 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 3 |
| container_start_page | 186 |
| container_title | Oncology (Williston Park, N.Y.) |
| container_volume | 36 |
| creator | Bryson, Evan B |
| description | Should clinicians be aware of any drug interactions? [...]there are no drug interactions to watch for with this product. Overall, the approval of amivantamab is a positive development for patients with lung cancer, and it adds another targeted option for those patients with limited therapy options after progression on platinum-based chemotherapy. Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_journals_2802945702</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A698546244</galeid><sourcerecordid>A698546244</sourcerecordid><originalsourceid>FETCH-LOGICAL-g249t-daf5ce46a7efebc7117ee4d1146283d9ea2f582a84b4feb99ebe0cadaded68623</originalsourceid><addsrcrecordid>eNptzU1rg0AQBmAPLTRN-x-EQm-WdbOuu9CLWG0CSQxioD3J6I6J4kfrmvTv19IeUpA5vDA878yVMSNCEksSad8Yt1pXhFDOiZgZz8HbLogT0482m2CbePG7GW3NZBmYuzh62fvJT4ardWBGoek15RnaARrIrHNTfd0Z1wXUGu__cm7swyDxl9Y6el353to6UCYHS0Hh5Mg4uFhglru27SIyZduMU7FQEoEWjqAgWMZGICVmSHJQoFBxwelibjz83v3ou88T6iGtulPfji9TKgiVzHHJhTpAjWnZFt3QQ96UOk89LoUzfmNsVNaEOmCLPdRdi0U5rv_5pwk_jsKmzCcLjxeFI0I9HHVXn4aya_Ul_AbV6ngN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2802945702</pqid></control><display><type>article</type><title>EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Amivantamab-vmjw</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Bryson, Evan B</creator><creatorcontrib>Bryson, Evan B</creatorcontrib><description>Should clinicians be aware of any drug interactions? [...]there are no drug interactions to watch for with this product. Overall, the approval of amivantamab is a positive development for patients with lung cancer, and it adds another targeted option for those patients with limited therapy options after progression on platinum-based chemotherapy. Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study.</description><identifier>ISSN: 0890-9091</identifier><language>eng</language><publisher>Monmouth Junction: Intellisphere, LLC</publisher><subject>Cancer therapies ; Care and treatment ; Chemotherapy ; Drug dosages ; Drug interactions ; Edema ; FDA approval ; Lung cancer ; Lung cancer, Non-small cell ; Metastasis ; Monoclonal antibodies ; Mutation ; Oncology ; Patients ; Targeted cancer therapy ; Tumors</subject><ispartof>Oncology (Williston Park, N.Y.), 2022-03, Vol.36 (3), p.186</ispartof><rights>COPYRIGHT 2022 Intellisphere, LLC</rights><rights>Copyright MultiMedia Healthcare Inc. 2022</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids></links><search><creatorcontrib>Bryson, Evan B</creatorcontrib><title>EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Amivantamab-vmjw</title><title>Oncology (Williston Park, N.Y.)</title><description>Should clinicians be aware of any drug interactions? [...]there are no drug interactions to watch for with this product. Overall, the approval of amivantamab is a positive development for patients with lung cancer, and it adds another targeted option for those patients with limited therapy options after progression on platinum-based chemotherapy. Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study.</description><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Drug dosages</subject><subject>Drug interactions</subject><subject>Edema</subject><subject>FDA approval</subject><subject>Lung cancer</subject><subject>Lung cancer, Non-small cell</subject><subject>Metastasis</subject><subject>Monoclonal antibodies</subject><subject>Mutation</subject><subject>Oncology</subject><subject>Patients</subject><subject>Targeted cancer therapy</subject><subject>Tumors</subject><issn>0890-9091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptzU1rg0AQBmAPLTRN-x-EQm-WdbOuu9CLWG0CSQxioD3J6I6J4kfrmvTv19IeUpA5vDA878yVMSNCEksSad8Yt1pXhFDOiZgZz8HbLogT0482m2CbePG7GW3NZBmYuzh62fvJT4ardWBGoek15RnaARrIrHNTfd0Z1wXUGu__cm7swyDxl9Y6el353to6UCYHS0Hh5Mg4uFhglru27SIyZduMU7FQEoEWjqAgWMZGICVmSHJQoFBxwelibjz83v3ou88T6iGtulPfji9TKgiVzHHJhTpAjWnZFt3QQ96UOk89LoUzfmNsVNaEOmCLPdRdi0U5rv_5pwk_jsKmzCcLjxeFI0I9HHVXn4aya_Ul_AbV6ngN</recordid><startdate>20220301</startdate><enddate>20220301</enddate><creator>Bryson, Evan B</creator><general>Intellisphere, LLC</general><general>MultiMedia Healthcare Inc</general><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20220301</creationdate><title>EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Amivantamab-vmjw</title><author>Bryson, Evan B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-g249t-daf5ce46a7efebc7117ee4d1146283d9ea2f582a84b4feb99ebe0cadaded68623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Drug dosages</topic><topic>Drug interactions</topic><topic>Edema</topic><topic>FDA approval</topic><topic>Lung cancer</topic><topic>Lung cancer, Non-small cell</topic><topic>Metastasis</topic><topic>Monoclonal antibodies</topic><topic>Mutation</topic><topic>Oncology</topic><topic>Patients</topic><topic>Targeted cancer therapy</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bryson, Evan B</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Oncology (Williston Park, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bryson, Evan B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Amivantamab-vmjw</atitle><jtitle>Oncology (Williston Park, N.Y.)</jtitle><date>2022-03-01</date><risdate>2022</risdate><volume>36</volume><issue>3</issue><spage>186</spage><pages>186-</pages><issn>0890-9091</issn><abstract>Should clinicians be aware of any drug interactions? [...]there are no drug interactions to watch for with this product. Overall, the approval of amivantamab is a positive development for patients with lung cancer, and it adds another targeted option for those patients with limited therapy options after progression on platinum-based chemotherapy. Amivantamab in EGFR exon 20 insertion–mutated non–small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study.</abstract><cop>Monmouth Junction</cop><pub>Intellisphere, LLC</pub></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0890-9091 |
| ispartof | Oncology (Williston Park, N.Y.), 2022-03, Vol.36 (3), p.186 |
| issn | 0890-9091 |
| language | eng |
| recordid | cdi_proquest_journals_2802945702 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Cancer therapies Care and treatment Chemotherapy Drug dosages Drug interactions Edema FDA approval Lung cancer Lung cancer, Non-small cell Metastasis Monoclonal antibodies Mutation Oncology Patients Targeted cancer therapy Tumors |
| title | EXPERT COMMENTARY ON THE PRODUCT PROFILE OF Amivantamab-vmjw |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T18%3A41%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=EXPERT%20COMMENTARY%20ON%20THE%20PRODUCT%20PROFILE%20OF%20Amivantamab-vmjw&rft.jtitle=Oncology%20(Williston%20Park,%20N.Y.)&rft.au=Bryson,%20Evan%20B&rft.date=2022-03-01&rft.volume=36&rft.issue=3&rft.spage=186&rft.pages=186-&rft.issn=0890-9091&rft_id=info:doi/&rft_dat=%3Cgale_proqu%3EA698546244%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2802945702&rft_id=info:pmid/&rft_galeid=A698546244&rfr_iscdi=true |